Plus Therapeutics Regains Compliance with Nasdaq Listing Requirements
05/16/2023 - 07:00 AM
AUSTIN, Texas, May 16, 2023 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. PSTV $1.00 per share or greater. Therefore, the Company has regained compliance with Listing Rule 5550(a)(2). Accordingly, Nasdaq has advised that the matter is now closed.
About Plus Therapeutics Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company developing targeted radiotherapeutics for difficult-to-treat cancers of the central nervous system with the potential to enhance clinical outcomes for patients. Combining image-guided local beta radiation and targeted drug delivery approaches, the Company is advancing a pipeline of product candidates with lead programs in recurrent glioblastoma (GBM) and leptomeningeal metastases (LM). The Company has built a robust supply chain through strategic partnerships that enable the development, manufacturing and future potential commercialization of its products. Plus Therapeutics is led by an experienced and dedicated leadership team and has operations in key cancer clinical development hubs including Austin and San Antonio, Texas. For more information, visit https://plustherapeutics.com/
Investor Contact Peter.Vozzo@westwicke.com
Media Contact Terri.Clevenger@westwicke.com
PSTV Rankings
N/A Ranked by Stock Gains
PSTV Stock Data
Industry
Surgical and Medical Instrument Manufacturing
Sector
Manufacturing
Tags
Health Technology, Biotechnology, Manufacturing, Surgical and Medical Instrument Manufacturing
Country
US
City
Austin
About PSTV
plus therapeutics, inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and manufacture of treatments for cancer and other diseases. its lead product candidate is doceplus, a protein-stabilized pegylated liposomal formulation of docetaxel for the treatment of small cell lung cancer. the company is also involved in developing doxoplus, a generic pegylated liposomal encapsulated doxorubicin to treat breast and ovarian cancer, multiple myeloma, and kaposi's sarcoma. it has a license agreement with nanotx, corp. to develop and commercialize nanotx's glioblastoma treatment. the company was formerly known as cytori therapeutics, inc. and changed its name to plus therapeutics, inc. in july 2019. plus therapeutics, inc. was founded in 1996 and is headquartered in austin, texas.
